Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant
동종 골수 이식 후 2년 미만의 환자에서 1차 COVID-19 예방 접종에 대한 체액 및 세포 반응 손상
Article
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus-2
adverse outcome
adverse outcomes
Allogeneic
allogeneic bone marrow transplant
analysed
anti-S IgG
Anti-spike
BNT162b2
Bone marrow
booster
Cell
Cell-mediated immunity
cellular response
ChAdOx1
Cohort
coronavirus disease
Coronavirus disease 2019
Coronavirus disease 2019 (COVID-19)
Coronavirus-2
COVID-19
COVID-19 vaccination
Critical
defined
enzyme-linked immunospot
Evidence
evidence of
haematopoietic stem cell transplant (HSCT)
HCs
healthy control
high risk
HSCT
HSCT recipient
HSCT recipients
humoral
IFNγ
IgG
Immunoglobulin
Immunoglobulin G
ImmunoSpot
Impaired
interferon
less
majority
Patient
Prophylactic
prophylactic measure
prophylactic measures
rate of seroconversion
recipient
respiratory
responders
Seroconversion
Severe acute respiratory syndrome
severe acute respiratory syndrome Coronavirus
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
significantly higher
significantly lower
stem cell
T-cell
T-cell Response
T-cell responses
These data
titre
Transplant
vaccination schedule
Vaccination strategy
Vaccine
vaccine immunogenicity
Vaccines
variants
[DOI] 10.1111/bjh.18312 PMC 바로가기 [Article Type] Article
[DOI] 10.1111/bjh.18312 PMC 바로가기 [Article Type] Article